ABSTRACT
Experimental inhibition of the (pro)renin receptor [(P)RR] is a promising therapeutic strategy in different disease models ranging from cardiorenal to oncological entities. Here, we briefly review the direct protein-protein interaction partners of the (P)RR and the plethora of distinct diseases in which the (P)RR is involved. The first structural work on the (P)RR using AlphaFold, which was recently published by Ebihara et al., is the center of this mini-review since it can mechanistically link the protein-protein interaction level with the pathophysiological level. More detailed insights into the 3D structure of the (P)RR and its interaction domains might guide drug discovery on this novel target. Finally, antibody- and small molecule-based approaches to inhibit the (P)RR are shortly discussed.
PMID:37885110 | DOI:10.2174/0113894501250617231016052930
11:03
PubMed articles on: Cardio-Oncology
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
Nat Med. 2023 Oct 26. doi: 10.1038/s41591-023-02591-2. Online ahead of print.
Comments
Post a Comment
اكتب تعليق حول الموضوع